FUNCTIONAL MEDICINE BLOG
Includes over 800 monographs reporting on emerging studies in the medical and scientific literature of practical clinical importance, easily searched for content.
Bisphosphonates increase risk of atypical fracture
More evidence that bisphosphonates (Fosamax® (alendronate), Boniva® (ibandronate), Actonel® (risedronate), Reclast® (zoledronic acid), etc.) by increasing bone density while sacrificing bone health increase the risk of atypical fractures is presented in a study just published in the journal Family Practice.
Fractures and other complications of osteoporosis drugs
Fractures and other complications of osteoporosis drugs